Stock ABOS ACUMEN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Real-time Estimate Cboe BZX
Other stock markets
 17:51:09 01/05/2024 BST 		5-day change 1st Jan Change
3.185 USD -1.09% Intraday chart for Acumen Pharmaceuticals, Inc. -0.47% -17.58%
04-04 Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug MT
04-04 Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug
Borsa svizzera chiude in rialzo, SMI +0,64%
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease
Acumen Pharmaceuticals Files $200 Million Mixed Shelf
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer
Acumen Pharmaceuticals Secures $50 Million Credit Facility
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease
Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer?s During Symposium At the 16Th Annual Clinical Trials on Alzheimer?s Disease
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Acumen Pharmaceuticals Prices Upsized $130 Million Common Stock Offering
Wall Street sluit hoger
Wall Street op winst
Top Midday Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABOS Stock
  4. News Acumen Pharmaceuticals, Inc.
  5. Other languages